(Q22001064)
Statements
Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model (English)
0 references
Darren Shafren
1 reference
Min Quah
1 reference
Yvonne Wong
1 reference
Robert HI Andtbacka
1 reference
Howard L Kaufman
1 reference
Gough G Au
1 reference
2014
0 references
2
0 references
Suppl 3
0 references
P125
0 references